Kurve Technology, a company in nasal drug delivery devices, announced that industry 'thought leader' Sveinbjorn Gizurarson has joined its scientific advisory board as a member
Gizurarson has extensive research and business experience in the development of nasal drug and vaccine delivery systems.
In 1991, Gizurarson founded Lyfjathroun Biopharmaceuticals, a nasal drug delivery company that initially focused on the safe and non-invasive nasal delivery of antigens and currently specializes on the delivery of rapid-onset nasal products.
Gizurarson served as Lyfjathroun's CEO between 1999 and 2005.
Gizurarson's research is widely published, and he has served on journal editorial boards as well as on international government and academic bodies handling issues related to life sciences.
Currently a professor of pharmacy and clinical therapeutics at the University of Iceland, Gizurarson has served on the faculty since 1991 after receiving his PhD from the Danish University of Pharmaceutical Sciences.
"We are honoured by Dr Gizurarson's decision to to help Kurve Technology as we strive to be a market leader in nasal drug delivery products.
"His expertise and experience will contribute enormously to our product development and clinical programmes," said Marc Giroux, CEO of Kurve Technology.
"Kurve Technology is working hard on developing truly innovative nasal drug delivery device technologies," said Gizurarson.
"There is a major unmet medical need in the nasal delivery space and I look forward to being able to contribute to Kurve Technology's exciting research and development efforts."
